* Integra Lifesciences Holdings Corp IART.OQ IART.O is
expected to show a rise in quarterly revenue when it reports
results on July 29 for the period ending June 30 2024
* The Princeton New Jersey-based company is expected to
report a
8.4% increase in revenue to $413.154 million from $381.27
million a year ago, according to the mean estimate from 10
analysts, based on LSEG data.The company's guidance on May 6
2024, for the period ended June 30, was for revenue between
$411.00 million and $416.00 million.
* LSEG's mean analyst estimate for Integra Lifesciences
Holdings
Corp is for earnings of 62 cents per share. The company's EPS
guidance on May 6 2024, for the period ended June 30, was
between $0.60 and $0.65
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 8
"hold" and 3 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Integra
Lifesciences Holdings Corp is $31.00, below its last closing
price of $31.53.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 0.55 0.55 0.55 Met -0.3
Dec. 31 2024 0.90 0.90 0.89 Missed -1.5
Sep. 30 2023 0.78 0.78 0.76 Missed -2.3
Jan. 1 0001 0.57 0.57 0.71 Beat 24.8
Jan. 0.74 0.74 0.74 Met 0.4
1 0001
Jan. 1 0001 0.91 0.90 0.94 Beat 4.1
Sep. 30 2022 0.71 0.72 0.86 Beat 19.5
Jan. 1 0001 0.80 0.80 0.81 Beat 1.6
This summary was machine generated July 26 at 13:31 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)